~~<i id='BFF964370C'><strike id='BFF964370C'><tt id='BFF964370C'><pre id='BFF964370C'></pre></tt></strike></i>~~

Home» Wikipedia» fashion

fashion

author：knowledge 2025-10-04 06:43:25 Page View：72826

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China
Next article： New air purifier tech could be key to improving indoor air quality

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

First U.S. drug developed to treat liver disease MASH is approved

AdobeTheFoodandDrugAdministrationonThursdayapprovedthefirstmedicinedevelopedspecificallytotreatthese

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Iran'sPresidentEbrahimRaisi,center,andKenya'sPresidentWilliamRuto,right,arrivetogiveajointpressconfe